TY - JOUR
T1 - Treatment effects on neurometabolite levels in schizophrenia
T2 - A meta-analysis dataset of proton magnetic resonance spectroscopy
AU - Kubota, Manabu
AU - Moriguchi, Sho
AU - Takahata, Keisuke
AU - Nakajima, Shinichiro
AU - Horita, Nobuyuki
N1 - Funding Information:
We thank Drs. Jean Théberge and Edith J Liemburg for providing us with additional 1 H-MRS data. This work was supported in part by Grants-in-Aid for Young Scientists ( 16K19790 [B] and 19K17101 to MK) from the Japan Society for the Promotion of Science . The agency had no further role in the research design, collection, analysis or interpretation of the data, writing of the report, or in the decision to submit the paper for publication.
Publisher Copyright:
© 2020 The Author(s)
PY - 2020/8
Y1 - 2020/8
N2 - This article describes a dataset for a meta-analysis that aimed to investigate the effects of treatment on the neurometabolite status in patients with schizophrenia (DOI of original article: https://doi.org/10.1016/j.schres.2020.03.069 [1]). The data search was performed with MEDLINE, Embase, and PsycINFO. The neurometabolites investigated include glutamate, glutamine, glutamate + glutamine, gamma-aminobutyric acid, N-acetylaspartate, and myo-inositol, and the regions of interest (ROIs) include the frontal cortex, temporal cortex, parieto-occipital cortex, thalamus, basal ganglia, and hippocampus. The meta-analysis was conducted with a random-effects model, and the use of the standardized mean difference method between pre- and post-treatment of subjects for neurometabolites in each ROI of three patient groups or more. The dataset covers raw data of 39 patient groups (773 patients with schizophrenia at follow-up) with neurometabolite levels measured by magnetic resonance spectroscopy both before and after treatment. Furthermore, it contains details of clinical characteristics and treatment types for each group. Therefore, the data would be useful for a reinvestigation of treatment effects on the neurometabolite status from diverse points of view, as well as for the development of future treatment strategies for psychiatric diseases.
AB - This article describes a dataset for a meta-analysis that aimed to investigate the effects of treatment on the neurometabolite status in patients with schizophrenia (DOI of original article: https://doi.org/10.1016/j.schres.2020.03.069 [1]). The data search was performed with MEDLINE, Embase, and PsycINFO. The neurometabolites investigated include glutamate, glutamine, glutamate + glutamine, gamma-aminobutyric acid, N-acetylaspartate, and myo-inositol, and the regions of interest (ROIs) include the frontal cortex, temporal cortex, parieto-occipital cortex, thalamus, basal ganglia, and hippocampus. The meta-analysis was conducted with a random-effects model, and the use of the standardized mean difference method between pre- and post-treatment of subjects for neurometabolites in each ROI of three patient groups or more. The dataset covers raw data of 39 patient groups (773 patients with schizophrenia at follow-up) with neurometabolite levels measured by magnetic resonance spectroscopy both before and after treatment. Furthermore, it contains details of clinical characteristics and treatment types for each group. Therefore, the data would be useful for a reinvestigation of treatment effects on the neurometabolite status from diverse points of view, as well as for the development of future treatment strategies for psychiatric diseases.
KW - Antipsychotic
KW - Gamma-aminobutyric acid
KW - Glutamate
KW - Glutamine
KW - MRS
KW - Myo-inositol
KW - N-acetylaspartate
KW - Psychosis
UR - http://www.scopus.com/inward/record.url?scp=85087072837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087072837&partnerID=8YFLogxK
U2 - 10.1016/j.dib.2020.105862
DO - 10.1016/j.dib.2020.105862
M3 - Article
AN - SCOPUS:85087072837
VL - 31
JO - Data in Brief
JF - Data in Brief
SN - 2352-3409
M1 - 105862
ER -